Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Objectives: Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD).

The primary outcome measure was 25OHD level after a follow-up period.Results: A total of 173 patients were analysed.

Who Took Part

The study group was 173 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Objectives: Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD).

The primary outcome measure was 25OHD level after a follow-up period.Results: A total of 173 patients were analysed.

The subject headings attached to it are Cholecalciferol, Czech Republic, Inflammatory Bowel Diseases, Logistic Models, Multivariate Analysis, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords body weight, dietary supplements and vitamin D intake.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 173 patients.

The publication is from 2020 (Scandinavian journal of gastroenterology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.